Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 94.88B 86.45B 80.02B 72.38B 136B 8,861B 142B 967B 384B 4,788B 356B 349B 15,168B P/E 2026 *
16x
P/E 2027 * 15.2x
Enterprise Value 87.71B 79.92B 73.98B 66.92B 126B 8,192B 131B 894B 355B 4,427B 329B 322B 14,022B EV / Sales 2026 *
4.66x
EV / Sales 2027 * 4.08x
Free-Float
72.51%
Yield 2026 *
0.4%
Yield 2027 * 0.42%
1 day-2.35%
1 week-3.76%
Current month-0.49%
1 month+16.77%
3 months+13.96%
6 months+46.64%
Current year+19.62%
1 week 920.24
Extreme 920.24
972.24
1 month 789.69
Extreme 789.69
991.73
Current year 591.52
Extreme 591.52
991.73
1 year 591.52
Extreme 591.52
991.73
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 76 08/01/1988
Date Insider Type Main position Quantity % Market Cap. Importance
4/11/26 Exercice

SVP Controller

11,828 0.0117%
3/11/26 Exercice

Director

22,317 0.0221%
3/11/26 Don

Chief Technology Officer

-1,054 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-2.35%-3.76%+27.30%+15.07% 94.88B
-2.29%-6.00%+31.17%+128.34% 1,232B
-2.04%-4.73%+33.57%+78.34% 656B
-0.86%-3.88%+21.24%+105.02% 506B
-1.04%-0.67%+30.16%+68.01% 382B
-3.61%-9.76%+37.73%+30.53% 340B
-3.22%-4.14%+24.75%+51.30% 294B
-2.51%-4.26%-1.93%+29.67% 278B
-1.14%-6.26%+27.57%+65.35% 240B
-1.45%-1.89%+30.94%+120.72% 210B
Average -1.61%-2.22%+26.25%+69.23% 423B
Weighted average by Cap. -1.19%-2.64%+27.87%+86.17%

Financials

2026 *2027 *
Net sales 18.81B 17.14B 15.87B 14.35B 26.93B 1,757B 28.18B 192B 76.09B 950B 70.59B 69.11B 3,008B 20.17B 18.37B 17.01B 15.39B 28.86B 1,883B 30.21B 206B 81.56B 1,018B 75.66B 74.08B 3,224B
Net income 6.43B 5.85B 5.42B 4.9B 9.2B 600B 9.63B 65.51B 25.99B 324B 24.11B 23.6B 1,027B 6.56B 5.98B 5.53B 5B 9.39B 613B 9.83B 66.87B 26.53B 331B 24.61B 24.09B 1,049B
Net Debt -7.17B -6.53B -6.05B -5.47B -10.26B -669B -10.74B -73.08B -28.99B -362B -26.89B -26.33B -1,146B -12.52B -11.4B -10.56B -9.55B -17.91B -1,169B -18.75B -128B -50.62B -632B -46.96B -45.98B -2,001B
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
19/11/26 US$923.34 -2.35% 718,039
18/11/26 US$945.53 -1.28% 705,406
17/11/26 US$957.76 +0.56% 933,408
16/11/26 US$952.40 -0.32% 700,861
13/11/26 US$955.47 +0.45% 1,165,717
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
923.34USD
Average target price
991.00USD
Spread / Average Target
+7.33%
  1. Stock Market
  2. Stocks
  3. REGN Stock